advertisement

Sanofi reports flat 2015 earnings

PARIS (AP) - French drug maker Sanofi says its bottom line was roughly stable last year as it advanced efforts to reshape its drug portfolio and pursue research and development tie-ups in oncology and diabetes.

Sanofi made 4.29 billion euros ($4.8 billion) last year, compared to 4.39 billion in 2014. In a statement, Sanofi said it "made meaningful progress with key launches, multiple business development activities and our efforts to simplify the organization."

In December Sanofi and German pharmaceutical company Boehringer Ingelheim said they are pursuing an asset swap that would see the German firm take over Sanofi's Merial animal health unit, which is valued at 11.4 billion euros. Sanofi is to acquire a large part of Boehringer's consumer health care business.

French drug maker Sanofi CEO Olivier Brandicourt presents the company's 2015 full year results in Paris, Tuesday Feb. 9, 2016. Sanofi says its bottom line was roughly stable last year as it advanced efforts to reshape its drug portfolio and pursue research and development tie-ups in oncology and diabetes. Sanofi made 4.29 billion euros ($4.8 billion) last year, compared to 4.39 billion in 2014. (AP Photo/Jacques Brinon) The Associated Press
French drug maker Sanofi CEO Olivier Brandicourt presents the company's 2015 full year results in Paris, Tuesday Feb. 9, 2016. Sanofi says its bottom line was roughly stable last year as it advanced efforts to reshape its drug portfolio and pursue research and development tie-ups in oncology and diabetes. Sanofi made 4.29 billion euros ($4.8 billion) last year, compared to 4.39 billion in 2014. (AP Photo/Jacques Brinon) The Associated Press
Article Comments
Guidelines: Keep it civil and on topic; no profanity, vulgarity, slurs or personal attacks. People who harass others or joke about tragedies will be blocked. If a comment violates these standards or our terms of service, click the "flag" link in the lower-right corner of the comment box. To find our more, read our FAQ.